Checkmate 577:Health-related quality of life (HRQoL) in a randomized, double-blind phase III study of nivolumab (NIVO) versus placebo (PBO) as adjuvant treatment in patients (pts) with resected esophageal or gastroesophageal junction cancer (EC/GEJC).

Eric Van Cutsem,Prianka Singh,James M. Cleary,Ronan J. Kelly,Markus Moehler,Jarosław Kużdżał,Guillermo Mendez,Satoru Motoyama,Elena Elimova,Cecile Grootscholten,Xiaowu Sun,Fiona Taylor,Rachael Lawrance,Brad Padilla,Alejandro Moreno-Koehler,Jenny Zhang,Steven I Blum,Jaffer A. Ajani

Checkmate 577:Health-related quality of life (HRQoL) in a randomized, double-blind phase III study of nivolumab (NIVO) versus placebo (PBO) as adjuvant treatment in patients (pts) with resected esophageal or gastroesophageal junction cancer (EC/GEJC).

2021

Eric Van Cutsem
Prianka Singh
James M. Cleary
Ronan J. Kelly
Markus Moehler
Jarosław Kużdżał
Guillermo Mendez
Satoru Motoyama
Elena Elimova
Cecile Grootscholten
Xiaowu Sun
Fiona Taylor
Rachael Lawrance
Brad Padilla
Alejandro Moreno-Koehler
Jenny Zhang
Steven I Blum
Jaffer A. Ajani

167Background: NIVO is the first adjuvant therapy to provide a statistically significant and clinically meaningful improvement in disease-free survival (DFS) versus PBO in resected EC/GEJC followin...

Keywords:

Internal medicine
Gastroenterology
Cancer
health related quality of life
double blind
Adjuvant
Adjuvant therapy
Gastroesophageal Junction
Nivolumab
Placebo
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations